Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.42 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
STRO 3.42 0.00(0.00%)
Will STRO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STRO
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
Other News for STRO
CVAC, SBNY and CRMD are among after hour movers
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Sutro Biopharma price target lowered by $7 at Truist, here's why
Wall Street Analysts Are Bullish on Top Healthcare Picks
Sutro Biopharma price target lowered by $1 at Piper Sandler, here's why